Lipocine Inc 's Revenue in the fiscal year 2025 $ 1.98 millions
Lipocine Inc 's Revenue in the fiscal year 2024 $ 11.20 millions
Lipocine Inc 's Revenue in the fiscal year 2023 $ -2.85 millions
Lipocine Inc 's Revenue in the fiscal year 2022 $ 1.07 millions
Lipocine Inc 's Revenue in the fiscal year 2021 $ 16.14 millions
LPCN Revenue third quarter 2026 Y/Y Growth Comment
Lipocine Inc achieved in the third quarter 2026, above Company average Revenue surge of 1981.88% year on year, to $ 2.29 millions.
Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 185 other companies have achieved higher Revenue growth. While Lipocine Inc ' s Revenue doubling of 1981.88% ranks overall at the positon no. 3901 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Lipocine Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
8307.6 %
735.02 %
-100 %
(Mar 31 2024)
LPCN's III. Quarter Q/Q Revenue Comment
Lipocine Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 1105.3%, to $ 2.29 millions, from $0.19 millions in the second quarter. LPCN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Lipocine Inc 's Revenue growth quarter on quarter, overall rank is 213.
Lipocine Inc achieved in the III. Quarter 2026 above company average sequential Revenue doubling of 1105.3%, to $ 2.29 millions, from $0.19 millions in the second quarter. LPCN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Lipocine Inc 's Revenue growth quarter on quarter, overall rank is 213.
Lipocine Inc 's 12 Months Revenue Growth Year on Year
Lipocine Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -63.89% year on year, at Jun 30 2026 compare to the -47.49% decrease at Mar 31 2026. If the Lipocine Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $2 millions.
In the Healthcare sector 416 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2258 to 3044.
Lipocine Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -63.89% year on year, at Jun 30 2026 compare to the -47.49% decrease at Mar 31 2026. If the Lipocine Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $2 millions.
In the Healthcare sector 416 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2258 to 3044.
About Lipocine Inc Revenue Growth Rates (LPCN), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
2,356.46%